Straits Times Index
3,265.39 +40.22 (+1.25%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,789.98 +278.29 (+1.69%) FTSE 100
8,023.87 +128.02 (+1.62%) Bitcoin USD
66,390.30 +13.22 (+0.02%) CMC Crypto 200
1,402.08 -12.68 (-0.90%)
23andMe Holding Co. (ME)
After hours:
| Previous close | 0.4829 |
| Open | 0.5000 |
| Bid | 0.4585 x 1000 |
| Ask | 0.4654 x 700 |
| Day's range | 0.4525 - 0.5092 |
| 52-week range | 0.3500 - 2.2100 |
| Volume | |
| Avg. volume | 7,690,580 |
| Market cap | 222.335M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings date | 26 May 2024 - 30 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.23 |
Barrons.com23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid
In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.
GlobeNewswire23andMe announces CEO’s intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E
- Reuters
23andMe CEO Wojcicki considering taking firm private, filing shows
Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.
